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Background. Erythropoietin deﬁciency and anemia occur in Chronic Kidney Disease (CKD) and may be treated with
Erythropoietin Stimulating Agents (ESAs). The optimal hemoglobin, in non-End Stage Renal Disease CKD, is controversial.
Methods.Wereview three recent randomizedtrials in anemiain CKD: CHOIR, CREATE, andTREAT. Results.C H O I R( N = 1432)
wasterminatedearly withmorefrequent death andcardiovascularoutcomesin thehigherHbgroup (HR1.34:95%C.I.1.03–1.74,
P = .03). CREATE (N = 603) showed no diﬀerence in primary cardiovascular endpoints. Stroke was more common in the higher
Hb group (HR 1.92; 95% C.I. 1.38–2.68; P<. 001) in TREAT (N = 4038). Conclusions. There is no beneﬁt to an Hb outside the
10–12g/dL range in this population. To avoidtransfusionsand improve Quality ofLife, ESAs shouldbe used cautiously, especially
in patients with Diabetes, CKD, risk factors for stroke, and ESA resistance.
1.Introduction
Anemia is an expected feature of chronic kidney disease
(CKD)oncetheglomerularﬁltrationrate(GFR)dropsbelow
60mL/minute. The World Health Organization (WHO)
deﬁnes anemia as a hemoglobin (Hb) below 13g/dL for
adult males and postmenopausal women, and below 12g/dL
for premenopausal women [1]. The anemia of CKD, due
primarilytoerythropoietindeﬁciency,isusuallynormochro-
mic, normocytic, associated with shortened red blood cell
survival, and some degree of iron deﬁciency [2]. Prospective
cohort studies suggest a 1% prevalence of anemia for a GFR
of 60mL/minute, rising to 9% below30mL/minute, and 33–
67% for those with a GFR below 15mL/minute [2].
Recombinant human erythropoietin (rHU EPO) has
been available for the treatment of anemia of CKD since
the 1980s and supplanted the use of blood transfusions and
adrogenic steroids [3]. Improved quality of life scores was
a consistent ﬁnding in early studies involving rHU EPO
and CKD [4–6]. Nevertheless, even early literature revealed
accelerated hypertension, failure of vascular accesses, and
occasionally hyperkalemia [7]. Later, as the link between car-
diovasculardisease (CVD)andCKDbecamemoreevident,it
became clear that anemia was an independent risk factor for
developing Left Ventricular Hypertrophy and Heart Failure
[8]. Lacking the beneﬁts of any randomized, controlled,
clinical trials, use of Erythropoietin Stimulating Agents
(ESAs) became widespread, and the optimal hemoglobin to
limit cardiovascular events was unknown [9, 10].
Restoring the Hb to normal levels in patients with ESRD
on hemodialysis may be associated with an improvement
in quality of life and regression of LVH but possibly at
the expense of serious cardiovascular outcomes, particularly
among those in whom anemia is more diﬃcult to correct
[10]. Table 1 lists various recommendations for target Hb.
Until 2006, the most consistent ﬁnding seemed to be that
an Hb level between 11–13g/dL improved quality of life,
without increasing CVD risk [11–16]. Still, as several trials
have explored higher Hb targets, outcomes such as more
rapid progression of cancers and increased risk of death and
serious cardiovascular events have prompted a black box
warning on all ESAs [17–19].2 Anemia
Possibly lost in all of this is the wealth of data accumulat-
ed in the 1980s and 1990s showing improved quality of life
scoresandincreased vitality.AmongESRDpatientsreceiving
ESAs, Benz et al. showed statistically significant improve-
ments in Maintenance of Wakefullness Testing (MWT),
reductions in Arousing Periodic Limb Movements (PLMS),
and interestingly, the hematocrit in these patients was
normalized (mean hematocrit 42.3%) [4]. Revicki et al. in
1995 demonstrated signiﬁcant improvements in assessments
of energy (P<. 05), physical function (P<. 05), home man-
agement (P<. 05), social activity (P<. 05), and cognitive
function (P<. 05) among CKD patients assigned to receive
ESA versus conservative therapy without ESAs. In this trial,
79%of ESAtreated patientsachieved a Hematocrit levelover
36%[6].In1991,117patientswith anemiarelated tochronic
renal failure not yet requiring dialysis were randomized to
receive erythropoietin to correct anemia (hematocrit of 40%
for males, 35% for females) versus placebo. Energy levels
and work capacity improved signiﬁcantly in the group with
correctedanemia comparedwiththegroupwithuncorrected
anemia [5]. Painter demonstrated improvements in exercise
training with rHU EPO in patients with ESRD [20]. Finally,
Moiaetal. showed areduction inbleedingtime byincreasing
the Hb through the use of rHU EPO [21].
This review will focus on the three most recent clinical
trials(CHOIR,CREATE,andTREAT),eachofwhichassesses
the optimal Hb in patients with CKD stages III-V and
the associated cardiovascular outcomes [10, 22, 23]. Table 2
outlines the characteristics of each trial.
2.CREATE
The Cardiovascular Risk Reduction by Early Anemia Treat-
ment with Epoetin Beta trial (CREATE), published in 2006,
was a randomized, controlled, clinical trial enrolling 603
patients to study the cardiovascular beneﬁt of Epoetin Beta
in anemic patients (Hb level 11–12.5g/dL) with stages III-
IV CKD (GFR 15–35mL/minute/1.73m2). Patients were
randomly assigned to a target Hb in the normal range
(13–15g/dL, n = 301) versus a subnormal level (10.5–
11.5g/dL, n = 302). The primary endpoint was a composite
of 8 cardiovascular events which included time to a ﬁrst
cardiovascular event, sudden death, myocardial infarction,
acute heart failure, stroke, transient ischemic attack, angina
pectoris, or cardiac arrhythmia resulting in hospitalization,
and complication of peripheral vascular disease.
Secondary endpoints included death from any cause,
deathfrom cardiovascular causes,andhospitalizationfor any
cause among others. Patients who were expected to require
renal replacement therapy within six months, had advanced
cardiovascular disease, were recently transfused, or had non-
renal causes of anemia were excluded.
The study was powered to detect an annual reduced
incidence of primary endpoint of 15%. Initial demographic
data showed that the groups were largely similar with very
few exceptions. The vast majority of patients in the normal
Hb group received Epoietin beta (98%). In the subnormal
Hb group, 32% received Epoietin Beta in year one, 52% in
Table 1: Target hemoglobin in CKD/ESRD.
Society Year Target Hb (g/dL)
NKF-DOQI [16] 2007 11-12
Canadian Society of Nephrology [11] 1999 11-12
Japanese Society for Dialysis Therapy
[13, 14]
2004 10-11, 11-12∗
ERA-EDTA [12, 15] 2004 ≥11∗∗
∗In active younger patients.
∗∗With no upper limit.
yeartwo,and 76%attheendofthestudy.Attheendofstudy,
the Hb levels between the two groups diﬀered by 1.5g/dL.
Compared to the normal Hb group, the subnormal Hb
group did not experience signiﬁcantly more ﬁrst cardiovas-
cular events or decline in GFR, but time to initiation of
dialysis after 18 months of the trial was signiﬁcantly shorter
among those treated to a normal Hb (P = .03).Nevertheless,
fully 105 primary cardiovascular events occurred (58 in the
higher Hb group versus 47 in the lower Hb group, P =
NS). General health and physical function were signiﬁcantly
improved relative to the subnormal Hb group (P = .003
and P<. 001, resp.). The investigators concluded that early
complete correction of anemia did not reduce the risk of
cardiovascular events among anemic patients with stage III-
IV CKD.
3.CHOIR
The results of the Correction of Hemoglobin in Outcomes
and Renal Insuﬃciency (CHOIR) trial were also reported in
2006. The open-label randomized, controlled, clinical trial
enrolling 1432 patients with anemia (all with Hb below
11g/dL at enrollment, and na¨ ıve to ESAs) and CKD III-
IV (GFR between 15–50mL/minute/1.73m2)c o m p a r e dc a r -
diovascular and renal outcomes for two groups randomized
to receive Epoetin Alfa to achieve mean Hbs of 11.3g/dL
(N = 717) versus 13.5g/dL (N = 715). The primary end
point was the time to the composite of death, myocardial
infarction, hospitalization forc o n g e s t i v eh e a r tf a i l u r e( w i t h
the exclusion of renal replacement therapy), or stroke.
Secondary outcomes included the time to renal replacement
therapy, hospitalization for either cardiovascular causes or
any cause, and quality of life. Patients with uncontrolled
hypertension, active gastrointestinal bleeding, iron overload,
history of frequent transfusions, refractory iron deﬁciency
anemia, active cancer, angina pectoris, or previous ESA
treatment were excluded.
At baseline, patients in both groups were very similar
with respect to their demographics with few exceptions.
Originally, patients were to be followed for approximately 3
years and the study was powered to show a 25% reduction
in the composite event rate in the higher Hb group. All 1432
patients were included in the ﬁnal analysis in an intention to
treat model. Median followup was 16 months.
After 3 months, a diﬀerence in Hb values between the
2 groups was observed. Although the low Hb group wasAnemia 3
Table 2: Study characteristics.
Study N (pts) HB target
(g/dL)
ESA GFR range
(mL/min/1.73m2) Primary endpoint P value for primary
endpoints
CHOIR
(2006) [10]
603 13.5 versus
11.3
Epoetin Alfa 15–50 Death, MI, CHF, CVA 0.03 for composite favoring
lower Hb
CREATE
(2006) [22]
1432 13–15 versus
10.5–11.5
Epoetin Beta 15–35 Composite of 8 CV events,
CKD progression
NS for CV events.
0.03 for ESRD favoring
lower Hb group
TREAT
(2009) [23]
4038 13 versus 9 Darbepoetin Alfa 20–60 Death, CV Event, ESRD NS
largelyabletoreach theprespeciﬁedtargetHb,fewerpatients
in the high Hb group were able to reach their prespeciﬁed
target Hb. Not surprisingly, the low Hb group required a
signiﬁcantly lower dose of Epoetin alfa.
By May of 2005, the trial was terminated at the recom-
mendation of the data and safety monitoring board after
recording 125 eventsin thehigher Hb groupversus97 events
in the lower Hb group (HR, 1.34; 95% conﬁdence interval,
1.03–1.74; P = .03). These included deaths, myocardial
infarctions, strokes, and hospitalizations for congestive heart
failure. They concluded that the likelihood of showing a
beneﬁt in the higher Hb group was negligible. Although no
individual primary outcome reached statistical signiﬁcance,
there appeared to be a trend among the higher Hb group
towardhospitalizationforCHF(HR1.41,P = .07)anddeath
(HR 1.48, P = .07). Quality of life scores were similar among
the 2 groups.
4.TREAT
More recently, the Trial to Reduce cardiovascular Events
with Aranesp Therapy (TREAT) was conducted to look at
patients who are anemic (Hb less than 11g/dL) and had
Diabetic CKD III-IV (GFR 20–60mL/minute/1.73m2). This
randomized, controlled, clinical trial enrolled over 4000
patients and randomly assigned approximately 2000 patients
to be treated with Darbepoetin Alfa to achieve an Hb
of approximately 13g/dL, and the remainder of patients
received placebo and rescue Darbepoetin Alfa therapy if and
when the Hb fell below 9g/dL. The primary end points
included the composite outcomes of death or cardiovascular
eventand a compositeoutcomeoftime to deathorend-stage
renal disease. Secondary endpoints included time to death,
death from cardiovascular causes, rate of GFR decline, and
quality of life measures.
Relevant exclusion criteria included those with uncon-
trolled hypertension, previous cardiovascular events or kid-
ney transplantation, chemotherapy/radiation therapy, can-
cer, hematologic diseases, pregnancy, and those receiving
ESA therapy in the preceding 12 weeks. The demographics
of the patients in Darbepoetin Alfa group (N = 2012) and
the Placebo group (N = 2026) were similar in most respects
with the exception of a higher percentage of patients in the
Placebo group having a history of cardiovascular disease,
higher creatinine at baseline, and lower glycated Hb.
During this trial, the results of CHOIR were revealed
to the enrolled patients, but the study was not terminated.
The trial was powered to detect 20% risk reduction for the
primary endpoint among those targeted to a higher Hb.
Three months after the initiation of the trial, the median
achieved Hb level in the Darbepoetin Alfa group diﬀered
signiﬁcantly from that in the placebo group (12.5g/dL
versus 10.6g/dL, P<. 001). At the end of the trial,
there were no diﬀerences in the primary cardiovascular
composite endpoints (31.4% of patients in the treatment
arm versus 29.7% of patients in the placebo arm reached
a cardiovascular composite endpoint, P = .41). However,
a signiﬁcantly higher proportion of patients suﬀered fatal
or nonfatal stroke among those treated with Darbepoetin
Alfa (5% versus 2.6%, HR 1.92; 1.38–2.68, P<. 001),
despite no evident diﬀerence between blood pressures in
each group. The renal composite endpoint was reached by
32.4% of patients in the treatment arm and 30.5% in the
placebo arm (P = .29). A higher proportion of patients in
the placebo group required cardiac revascularization (5.8%
versus 4.2%, HR 0.71, 0.54–0.94, P = .02). Interestingly,
a signiﬁcantly higher proportion of patients randomized to
the placebo arm required transfusions versus those in the
treatment arm (24.5% versus 14.8%, HR for Aranesp 0.56;
95% conﬁdence interval, 0.49–0.65; P<. 001). There was
a nonstatistically signiﬁcant trend towards a higher rate of
cancer deaths among those in the treated group (39 versus
25, P = .08).
5.Conclusions
These three clinical trials in anemic patients with non-ESRD
CKD each showed no clear beneﬁt to normalizing Hb in this
population, while in some cases showed harm. At best, these
trials do show improvements in quality of life particularly
with regard to vitality, physical function, and mental health.
The shorter time to dialysis seen in the CREATE trial, a
higher composite rate of death, myocardial infarction, and
hospitalization for CHF in the early-terminated CHOIR
study, and the higher stroke risk in the TREAT trial weigh
against these quality of life improvements and suggest
that normalizing Hb in this population is not warranted
and potentially hazardous. The lack of a diﬀerence in
cardiovascular outcomes in the placebo-controlled TREAT
trial, which enrolled twice as many patients as the other 24 Anemia
trials combined, is compelling given the paucity of placebo-
controlled trials in this population.
The mean Hb among placebo-treated patients in the
TREAT trial was 10.6g/dL and was 11.3g/dL and 11.6g/dL
in the lower Hb groups in the CHOIR and CREATE trials,
respectively. Still, 46 percent of patients assigned to the
placebo arm in TREAT received at least one dose of Darbe-
poetin alfa. Fully 76% of patients in the lower Hb group in
CREATE received Epoetin beta. Among those in the CHOIR,
study the mean dose of Epoetin Alfa for the lower Hb
group was approximately 6000 units per week. Nevertheless,
even among the more conservatively treated patients, the
incidence of serious cardiovascular and renal outcomes was
not negligible. In both CHOIR and CREATE, approximately
15%ofthose targeted toa lowerHb experienceda composite
endpoint (CHOIR)or a cardiovascular endpoint (CREATE).
Death or a cardiovascular endpoint occurred in nearly 30%
of patients assigned to the placebo group in TREAT.
The high prevalence of cardiovascular disease among
CKD patients is well known, and this burden of CVD
increases with theseverityoftheCKD[18].While itireason-
able to surmise that pharmacologically correcting anemia, in
lieu of transfusions, to some extent, is beneﬁcial to patients
with anemia and CKD, by virtue of reducing well-known
transmission of viruses, these trials oﬀer no convincing
data to establish a cutoﬀ lower (or upper) limit for anemia
management. Eckhardt et al. reviewed echocardiographic
data from CREATE and concluded that complete correction
of anemia exacerbated the prognosis of eccentric LVH [24].
Weineret al., however, concludedthat amongst patients with
CKD in the Atherosclerotic Risk in Communities Study,
Cardiovascular Health Study, Framingham Heart Study, and
Framingham Oﬀspring Study, LVH and anemia conferred
a higher risk of composite cardiovascular outcomes (HR
for LVH 1.67 95% CI 1.34–2.07 and HR for Anemia
1.51 95% CI 1.27–1.81). Weiner further showed that the
combination of anemia and LVH among patients with CKD
conferred greater than four times the risk of these outcomes
versus those without either comorbidity [25]. Besarab’s data
suggests that those requiring progressively higher ESA doses
t oa c h i e v eat a r g e tH bm a yh a v eh i g h e ri n c i d e n c eo fd e a t h
[26].
Eventhoughanemiacorrectionmayhaveasalutaryeﬀect
onLVHregression andreductionincardiovascularoutcomes
[27],this mustbeweighed against thedisappointing ﬁndings
in TREAT, CHOIR, and CREATE. While in 2009 the K-
DOQI Guidelines suggest that the target Hb “generally be
in the range of 11-12g/dL,” in the absence of compelling
data to the contrary, and in the spirit of doing no harm, it
m a yb em o r er e a s o n a b l et ot a r g e tt h eH ba ss p e c i ﬁ e db yt h e
package inserts which aim for 10–12g/dL. The highest Hb
target among those targeted to a lower Hb in the three trials
reviewed was 11.6 in the CREATE trial. Substantial dosage
reductions should occur as the Hb approaches 12g/dL.
Furthermore, particular attention should be paid to those
who respond slowly and require higher doses of ESAs, and
to those with Diabetes and CKD and risk factors for stroke.
Nevertheless, it would behoove the practitioner to recall
theQualityofLifebeneﬁtsconferredbyESAsinthestudiesin
the 1990s and avoid the knee-jerk response of underutiliza-
tion of these drugs. One more recent trial, only in abstract
form at this point, CAPRIT (The Complete Correction of
Post-Transplant Anemia reduces the Rate of Progression of
Chronic Allograft Nephropathy) may demonstrate a beneﬁt
to a higher hemoglobin. This randomized trial of 128
patients (at least one year after renal transplant) with CKD
III-IV (GFR 20–50mL/min) sought to determine if a higher
Hb wouldbe associated with a slower progression ofChronic
Allograft Nephropathy. Patients were randomized to a target
Hb of 13–15g/dL (Group A) versus 10.5–11.5g/dL (Group
B). At the end of the study, the Hb in Group A versus B was
12.9versus11.3g/dL(P<. 001),andaftertwoyears4(Group
A) versus 10 patients (Group B) reached ESRD (P<. 01).
At one year, the respective GFRs were 35.9 ± 17.2mL/min
(Group A) versus 30.8 ±12.1mL/min(GroupB)(P<. 025).
The incidenceofcardiovasculareventsdidnotdiﬀerbetween
groups [28].
In conclusion, ESA use reduces the need for transfu-
sions, improves quality of life and exercise tolerance, can
regress LVH, and may be of beneﬁt in retarding Chronic
Allograft Nephropathy. ESA use, however, is also associated
with poorer cardiovascular outcomes when used to target
hemoglobins higher than the prespeciﬁed package inserts
and possibly when used excessively in the setting of refactory
anemia [3, 4, 7, 8, 12, 14, 17, 19]. The data strongly suggest a
target Hbin the CKDpopulationno higherthan 10–12g/dL,
careful attention to underlying risks for cardiovascular
disease, and thorough evaluation of correctable causes of
anemia to prevent “overuse” of ESAs.
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